Indication
Nephrosis
2 clinical trials
2 products
Clinical trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseStatus: Terminated, Estimated PCD: 2022-11-01
Product
PlaceboProduct
GFB-887Clinical trial
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney DiseasesStatus: Terminated, Estimated PCD: 2022-11-02